Study of RBP-01 before surgery or radiation for eye melanoma
Part of Cancer, Eyes & vision clinical trials.
This trial tests a new drug, RBP-01, given before either surgery to remove the eye or radiation therapy, to see if it can help treat a type of eye cancer called uveal melanoma. It may offer a new option for people with larger tumors or those at risk of vision loss from standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Have a type of eye melanoma (in the choroid or ciliary body) that is localized (has not spread)
- Doctor recommends either removal of the eye (enucleation) or a radiation treatment called plaque brachytherapy that may cause significant vision loss
- Be in good enough health to carry out daily activities (ECOG 0-1)
- The melanoma is thicker than 4 mm
- If female and able to have children, must have a negative pregnancy test before starting
- Must not have previously been treated with a PKC inhibitor, have cancer that has spread (metastatic), have iris melanoma, have certain eye conditions (like ring melanoma, severe glaucoma, uveitis), or be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This trial tests a drug called darovasertib given before standard surgery for primary uveal melanoma (a type of eye cancer that hasn't spread). The goal is to see if the drug can shrink the tumor and improve outcomes.
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
This Phase 3 study tests whether taking melatonin after treatment for uveal melanoma can reduce the chance that the cancer returns or spreads to other parts of the body. It is aimed at people with higher-risk eye melanoma features.
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.